Dual driver in non-small cell lung carcinoma – therapeutic dilemma
Open Access
- 27 November 2021
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 7, 16-19
- https://doi.org/10.25259/ijmio_22_2021
Abstract
The presence of a targetable driver mutation in advanced non-small cell carcinoma is seen in about 40–50% of patients. The most common targetable driver identified is the mutation of the epidermal growth factor receptor gene. Conventionally, it was thought that these driver mutations of mutually exclusive. But due to the availability of a wider panel of molecular testing and highly sensitive methods of testing, there have been multiple case reports of more than one driver being identified in a single patient. Here in this series, we have described five such cases and have discussed the possible hypothesis and strategies in treatment.Keywords
This publication has 14 references indexed in Scilit:
- What, When, and How of Biomarker Testing in Non–Small Cell Lung CancerJournal of the National Comprehensive Cancer Network, 2017
- Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 casesOncotarget, 2017
- Current practices and guidelines for clinical next-generation sequencing oncology testingCancer Biology & Medicine, 2016
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitorAnnals of Oncology, 2014
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors PhosphorylationClinical Cancer Research, 2014
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014
- Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)PLOS ONE, 2013
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011